Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519561 | 1.00 | SMN1; SMN2 (0.72) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL21688483 | 1.00 | SMN1; SMN2 (0.72) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL23789641 | 0.97 | SMN1; SMN2 (0.68) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL1588408 | 0.96 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL4434481 | 0.96 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL7591866 | 0.96 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL1588404 | 0.96 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL22260724 | 0.96 | SMN1; SMN2 (0.78) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL23789637 | 0.95 | SMN1; SMN2 (0.66) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| SCHEMBL21688913 | 0.95 | SMN1; SMN2 (0.65) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109546-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| WO-2000004898-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2000-02-03 | — | — | WO | claimed |
| US-12472273-B2 | Sterilization process of timolol gel forming solution through aseptic filtration | SENTISS PHARMA PRIVATE LIMITED (IN) | 2025-11-18 | — | — | US | disclosed |
| US-12064440-B2 | Ophthalmic gel compositions of bimatoprost and timolol and associated methods | SOMERSET THERAPEUTICS, LLC (US) | 2024-08-20 | — | — | US | disclosed |
| US-12042502-B2 | Enhanced penetration ophthalmic compositions of bimatoprost and timolol | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| CN-117466835-A | Preparation method of 3-thiotimolol maleate | 承德医学院 | 2024-01-30 | — | — | CN | disclosed |
| US-20230338393-A1 | OPHTHALMIC GEL COMPOSITIONS OF BIMATOPROST AND TIMOLOL AND ASSOCIATED METHODS | SOMERSET THERAPEUTICS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230293541-A1 | METHODS OF TREATING OPHTHALMIC CONDITIONS WITH ENHANCED PENETRATION COMPOSITIONS OF BIMATOPROST AND TIMOLOL | SOMERSET THERAPEUTICS, LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230293547-A1 | ENHANCED PENETRATION OPHTHALMIC COMPOSITIONS OF BIMATOPROST AND TIMOLOL | SOMERSET THERAPEUTICS, LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230143595-A1 | A STERILIZATION PROCESS OF TIMOLOL GEL FORMING SOLUTION THROUGH ASEPTIC FILTRATION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-20080233053-A1 | nebulizer; eye-state detector, open or shut; reversibly actuatable radiation-source of sterilizing radiation; contactor for posterior eye; shut eye; vibrate eyelid; increase bioavailability to sclera, optic nerve, retina, brain, central nervous system, cerebral cavity, cerebrospinal fluid, spinal cord | PHARMALIGHT INC. (DE) | 2008-09-25 | — | — | US | disclosed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1748766-A1 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS COMPRISING A BETA ADRENERGIC RECEPTOR ANTAGONIST AND METHODS FOR TREATING OCULAR NEUROPATHIES | ALLERGAN, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005110380-A1 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS COMPRISING A BETA ADRENERGIC RECEPTOR ANTAGONIST AND METHODS FOR TREATING OCULAR NEUROPATHIES | ALLERGAN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050244458-A1 | Sustained release intraocular implants and methods for treating ocular neuropathies | ALLERGAN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| EP-0941218-B1 | ANTITHROMBOTIC ORGANIC NITRATES | NICOX SA (FR) | 2002-10-16 | — | — | EP | disclosed |
| US-6242432-B1 | ANTIHYPERTENSIVE ACTIVITY, ANTIHYPERSENSITIVE ACTIVITY; TREATMENT OF CARDIOVASCULAR DISEASE | NICOX S.A. (FR) | 2001-06-05 | — | — | US | disclosed |
| WO-1992018124-A1 | OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A β-ADRENERGIC ANTAGONIST | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042502-B2 | Enhanced penetration ophthalmic compositions of bimatoprost and timolol | PTGIS, PTGIR, MYOC | SMN1; SMN2 3072/4885BLM 2221/4885CYP1A2 468/4885 |
| US-12064440-B2 | Ophthalmic gel compositions of bimatoprost and timolol and associated methods | PTGIS, PTGIR, PTGS1 | SMN1; SMN2 4259/4885BLM 1433/4885CYP1A2 439/4885 |
| US-20230338393-A1 | OPHTHALMIC GEL COMPOSITIONS OF BIMATOPROST AND TIMOLOL AND ASSOCIATED METHODS | PTGIS, PTGIR, PTGS1 | SMN1; SMN2 4259/4885BLM 1433/4885CYP1A2 439/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | SMN1; SMN2 1501/4885BLM 2559/4885CYP1A2 2699/4885 |
| US-20230293547-A1 | ENHANCED PENETRATION OPHTHALMIC COMPOSITIONS OF BIMATOPROST AND TIMOLOL | PTGIS, PTGIR, MYOC | SMN1; SMN2 3072/4885BLM 2221/4885CYP1A2 468/4885 |
| US-20230293541-A1 | METHODS OF TREATING OPHTHALMIC CONDITIONS WITH ENHANCED PENETRATION COMPOSITIONS OF BIMATOPROST AND TIMOLOL | PTGIS, PTGIR, PTGS1 | SMN1; SMN2 3478/4885BLM 1513/4885CYP1A2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.